~ DiscGenics, Inc., a leading biopharmaceutical company focused on developing regenerative therapies for musculoskeletal degeneration, has announced that their recent clinical trial results have been published in the International Journal of Spine Surgery (IJSS). The article, titled "Allogeneic Disc Progenitor Cells Safely Increase Disc Volume and Improve Pain, Disability, and Quality of Life in Patients With Lumbar Disc Degeneration," was selected as one of the top three most influential articles published in the journal in 2024.

The study, which combined Phase I and II clinical trials, evaluated the safety and efficacy of allogeneic disc progenitor cell therapy (IDCT) for patients with painful lumbar degenerative disc disease (DDD). The results showed that a single intradiscal injection of high-dose IDCT (9,000,000 cells/mL) not only increased disc volume safely but also led to significant improvements in back pain, disability, and quality of life for up to two years post-injection.

Lead author and top enroller in the study, Dr. Matthew F. Gornet from The Orthopedic Center of St. Louis expressed his excitement about the positive outcomes. "The patient outcomes from this study are very encouraging," he said. "They demonstrate IDCT's ability to effectively reduce pain and disability associated with DDD while also potentially producing a regenerative effect within the degenerating disc."

More on Missouriar

• Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
• Canterbury Hotel Group Announces the Opening of the TownePlace Suites by Marriott Portland Airport
• Columbia Fire Department mutual aid hazardous materials incident, Callaway County, Dec. 3rd
• Heritage at South Brunswick's Resort-Style Amenities for Any Age and Every Lifestyle
• T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™

Dr. Gornet will be presenting the research at the upcoming International Society for the Advancement of Spine Surgery (ISASS) meeting in Miami on April 11th.

DiscGenics' Chief Executive Officer and Chairman of the Board, Flagg Flanagan, expressed gratitude for being recognized by ISASS and IJSS. He also thanked Dr. Gornet and all other study authors for their contributions to the article. "IDCT has shown great potential to change the way we treat patients with DDD," Flanagan said. "The momentum provided by this publication has been inspiring as we prepare to initiate Phase III clinical trials in the U.S."

In addition to the publication, DiscGenics has also received approval from the U.S. Food and Drug Administration (FDA) to proceed with Phase III clinical evaluation of IDCT. The company expects to begin enrolling subjects in the second quarter of 2025.

This groundbreaking research and recognition from ISASS and IJSS highlight the potential of IDCT as a game-changing therapy for patients with DDD. With continued progress and support, DiscGenics hopes to bring this innovative treatment to those in need in the near future.

---

Show All News | Report Violation